2026-02-26
NordicAST workshop in Malmö Hyllie, 12th-13th May 2026 - Registration is open!
Published at 2024.02.08
NordicAST would like to welcome you to the 2024 workshop. This year we will have a new location in Malmö Hyllie for the workshop, at the Arena Hotel.
The workshop will be on-site only and there will be many opportunities to meet and discuss with colleagues from other Nordic laboratories and the NordicAST committee members.
The program will cover topics such as automated reading of inhibition zones, clinical and AST aspects of non-tuberculosis mycobacteria, anaerobic AST and many other practical challenges in AST.
Preliminary program for the 2024 workshop.
Registration opens 7th February and will be closed 31st of March: https://jirango.com/cview/web/380f517b. Hotel rooms can be booked through the registration form.
NEW in this year's workshop: laboratory technicians/bioengineers, microbiologists in training and ph.d. students can present their work in a mini oral presentation session (4 minute presentations, followed by 2 minutes discussion) and register at a reduced fee of 2.900 SEK.
Send an abstract via https://forms.gle/Frz3NWyFAHB23h2X6 latest Sunday, March 17th, 23.59. You will receive a notification whether the abstract is accepted, latest March 24th, so you have one more week to register for the workshop – but in any case you are guaranteed a place at the workshop and hotel room. If accepted, you will receive a registration link for the reduced fee.
The abstract (max. 350 words) should cover any original work in the area of antimicrobial susceptibility testing and be written in English. We welcome work previously presented at conferences like ECCMID 2024 or NSCMID 2023.
We are looking forward to seeing many of you in Malmö in May!
NordicAST committee members
2026-02-26
NordicAST workshop in Malmö Hyllie, 12th-13th May 2026 - Registration is open!
2026-01-26
The 2026 NordicAST breakpoint tables v. 16.0 have been published
2025-11-27
New NordicAST BLBLI document: β-lactam-β-lactamase inhibitor combinations and novel β-lactams targeting Gram-negative bacteria